Inovio Pharmaceuticals (INO) Enterprise Value (2016 - 2025)
Inovio Pharmaceuticals (INO) has disclosed Enterprise Value for 16 consecutive years, with -$58.5 million as the latest value for Q4 2025.
- Quarterly Enterprise Value rose 13.22% to -$58.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$58.5 million through Dec 2025, up 13.22% year-over-year, with the annual reading at -$58.5 million for FY2025, 13.22% up from the prior year.
- Enterprise Value hit -$58.5 million in Q4 2025 for Inovio Pharmaceuticals, down from -$50.8 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$47.5 million in Q2 2025 to a low of -$518.6 million in Q1 2021.
- Historically, Enterprise Value has averaged -$216.3 million across 5 years, with a median of -$181.2 million in 2023.
- Biggest five-year swings in Enterprise Value: tumbled 194.45% in 2021 and later soared 56.94% in 2025.
- Year by year, Enterprise Value stood at -$401.3 million in 2021, then skyrocketed by 36.96% to -$253.0 million in 2022, then soared by 42.57% to -$145.3 million in 2023, then skyrocketed by 53.59% to -$67.4 million in 2024, then rose by 13.22% to -$58.5 million in 2025.
- Business Quant data shows Enterprise Value for INO at -$58.5 million in Q4 2025, -$50.8 million in Q3 2025, and -$47.5 million in Q2 2025.